126 related articles for article (PubMed ID: 16370393)
1. MDX-060. Medarex.
Hu XF; Xing PX
Curr Opin Investig Drugs; 2005 Dec; 6(12):1266-71. PubMed ID: 16370393
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
Ansell SM; Horwitz SM; Engert A; Khan KD; Lin T; Strair R; Keler T; Graziano R; Blanset D; Yellin M; Fischkoff S; Assad A; Borchmann P
J Clin Oncol; 2007 Jul; 25(19):2764-9. PubMed ID: 17515574
[TBL] [Abstract][Full Text] [Related]
3. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.
Heuck F; Ellermann J; Borchmann P; Rothe A; Hansen H; Engert A; von Strandmann EP
J Immunother; 2004; 27(5):347-53. PubMed ID: 15314543
[TBL] [Abstract][Full Text] [Related]
4. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
5. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
6. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
Cerveny CG; Law CL; McCormick RS; Lenox JS; Hamblett KJ; Westendorf LE; Yamane AK; Petroziello JM; Francisco JA; Wahl AF
Leukemia; 2005 Sep; 19(9):1648-55. PubMed ID: 16049514
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
8. CD30/Ki-1-positive anaplastic large cell lymphoma preceded by Hodgkin's disease.
Tsurumi H; Takahashi T; Moriwaki H; Muto Y
Int J Hematol; 1992 Aug; 56(1):99-102. PubMed ID: 1327272
[TBL] [Abstract][Full Text] [Related]
9. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.
Falini B; Pileri S; Pizzolo G; Dürkop H; Flenghi L; Stirpe F; Martelli MF; Stein H
Blood; 1995 Jan; 85(1):1-14. PubMed ID: 7803786
[No Abstract] [Full Text] [Related]
10. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Hodgkin's disease with Natulan].
Anglesio E
Minerva Med; 1965 Dec; 56(100):4402-6. PubMed ID: 5324896
[No Abstract] [Full Text] [Related]
12. Ofatumumab in the treatment of non-Hodgkin's lymphomas.
Karlin L; Coiffier B
Expert Opin Biol Ther; 2015 Jul; 15(7):1085-91. PubMed ID: 26043777
[TBL] [Abstract][Full Text] [Related]
13. Procarbazine (Natulan) in the treatment of Hodgkin's disease and other lymphomas.
Spies SK; Snyman HW
S Afr Med J; 1966 Dec; 40(44):1061-4. PubMed ID: 5334208
[No Abstract] [Full Text] [Related]
14. [Combination chemotherapy and synchronization therapy in lymphogranulomatosis and non-Hodgkin's lymphomas].
Klein HO
Hamatol Bluttransfus; 1976; 18():135-45. PubMed ID: 786808
[No Abstract] [Full Text] [Related]
15. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
[TBL] [Abstract][Full Text] [Related]
16. Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30+) lymphomas.
Delsol G; Blancher A; al Saati T; Ralfkiaer E; Lauritzen A; Bruigères L; Brousset P; Rigal-Huguet F; Mazerolles C; Robert A
Br J Cancer; 1991 Aug; 64(2):321-6. PubMed ID: 1716454
[TBL] [Abstract][Full Text] [Related]
17. CD30: an important new target in hematologic malignancies.
Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
Hartmann F; Renner C; Jung W; Pfreundschuh M
Leuk Lymphoma; 1998 Oct; 31(3-4):385-92. PubMed ID: 9869203
[TBL] [Abstract][Full Text] [Related]
19. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
20. Current treatment and immunotherapy of Hodgkin's lymphoma.
Klimm B; Schnell R; Diehl V; Engert A
Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
